recipient at 22°C and 37°C (selection of transconjugants in MacConkey agar with 2 mg/L of ceftazidime and 130 mg/L of azide) failed to yield transconjugants either for \( bla_{VIM-34} \) or \( bla_{SHV-12} \). The location of \( bla_{VIM-34} \), \( bla_{SHV-12} \) genes and plasmid characterization were accomplished by S1- and I-CeuI-PFGE, and identification of incompatibility groups. In both isolates, \( bla_{VIM-34} \), \( bla_{SHV-12} \) and repH12 probes hybridized in the same chromosomal band (I-CeuI-PFGE) whereas no signals were observed in the S1 gel, suggesting the acquisition of both \( bla \) genes by an IncH12 plasmid and subsequent plasmid (whole or in part) integration. A chromosomal location for \( bla \) genes, including \( bla_{VIM-34} \), has been occasionally observed in different Enterobacteriaceae species. 

The linkage of \( bla_{VIM-34} \) to class 1 integrons and Tn402 derivatives was investigated by PCR (intI1, 5’CS-3’CS region, orf5, orf6, IS1326, IS1353, IS6100) and sequencing. \( bla_{VIM-34} \) was located within an ~6 kb class 1 integron named In817 by INTEGRALL (http://integrall.bia.ua.pt/) (GenBank accession number JX185132), with an original array of gene sequences comprising \( bla_{VIM-34} \), aacA4, aphA15, aadA1b and catB2 (Figure S1; available as Supplementary data at JAC Online). The absence of \( tni_{O2} \) sequences and the high similarity detected with In70 and In113, identified in VIM-1-producing Achromobacter xylosoxidan, K. pneumoniae and E. coli isolates, suggests that the In817 integron might have arisen by both recombination and in vivo evolution events (Figure S1; available as Supplementary data at JAC Online). In summary, we present the first report of VIM-34, a VIM-1-like variant embedded in the novel integron type In817 on the chromosome of the intercontinental ST15 K. pneumoniae clone, associated with carbapenem susceptibility profiles similar to those observed for VIM-1. This study highlights the risk of further dissemination of the multidrug-resistant ST15 K. pneumoniae clone and genetic backgrounds containing metallo-\( \beta \)-lactamase genes in our country, which deserves future monitoring.

Acknowledgements

We thank Valquíria Alves and Antónia Read (Hospital Pedro Hispano, Matosinhos, Portugal) for the gift of strains.

Funding

This study was supported by Fundação para a Ciência e Tecnologia, which is part of the Ministry of Science, Technology and Innovation of Portugal (through grants no. PEst-C/QUI/UI006/2011, PTDC/AAC-AMB/103386/2008, EXPEDITION/0196/2012 and FCOMP-01-0124-FEDER-027745), Fundação Ensino e Cultura Fernando Pessoa, and an ESMID Research Grant 2012 awarded to Angela Novais. Carla Rodrigues was supported by Fundação para a Ciência e Tecnologia through grant no. SFRH/BD/84341/2012. Angela Novais was supported by a Marie Curie Intra European Fellowship within the 7th European Community Framework Programme (PIEF-GA-2009-255512).

Supplementary data

Figure S1 is available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).

References

11. Novais Â, Baquero F, Machado E et al. International spread and persistence of TEM-24 is caused by the confluence of highly penetrating Enterobacteriaceae clones and an IncAC\( _y \) plasmid containing \( Tn1696::TnI \) and \( IS5075::Tn21 \). Antimicrob Agents Chemother 2010; 54: 825–34.

J Antimicrob Chemother 2014
doi:10.1093/jac/dkt315
Advance Access publication 29 August 2013

Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates

Myung-Jin Choi and Kwan Soo Ko*

Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 440-746, Korea
Sir,

Although colistin resistance is rare, colistin-resistant *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* isolates have been reported worldwide, including Korea.\(^1\) The mutant selection window (MSW) hypothesis has been suggested as a new strategy to investigate the emergence of antimicrobial resistance. The mutant prevention concentration (MPC) is the drug concentration required to prevent the emergence of all single-step mutations from a susceptible population of more than 10\(^{10}\) cells; MPC as a measure of antibiotic potency allows the probability of resistance selection during the treatment of infected patients to be predicted.\(^2\)

In vitro time–kill experiments have suggested that the MPCs of colistin are high.\(^3\) We determined the MPCs of colistin for *A*. *baumannii*, *P*. *aeruginosa* and *K*. *pneumoniae* isolates.

Forty *A*. *baumannii* (20 imipenem resistant and 20 susceptible), 40 *P*. *aeruginosa* (20 imipenem resistant and 20 susceptible) and 33 *K*. *pneumoniae* (11 imipenem resistant and 22 susceptible) isolates from Korean hospitals were investigated. The MICs of imipenem and colistin were determined by a broth microdilution method according to CLSI guidelines.\(^4\) The MPC of colistin was determined as previously described.\(^5\) All resulting mutants grown within a colistin concentration range known as the MSW (8 mg/L) were stocked and stored at \(-80^\circ\)C for further study. Nucleotide sequences of pmrAB, phoPQ, parRS and lpxACD (pmrAB and lpxACD for *A. baumannii*, pmrAB, phoPQ and parRS for *P. aeruginosa*, and pmrAB and phoPQ for *K. pneumoniae*) were determined in single-step mutants to understand their association with the emergence of colistin resistance.

All isolates were susceptible to colistin: the MIC ranges of colistin were 0.5–1 mg/L, 1–2 mg/L and 0.06–4 mg/L for *A*. *baumannii*, *P*. *aeruginosa* and *K*. *pneumoniae*, respectively. The MPCs for the three Gram-negative species were very high and were unrelated to their colistin and imipenem MICs. All isolates except two *P*. *aeruginosa* isolates and one *K*. *pneumoniae* isolate showed an MPC \(\geq 64\) mg/L. In particular, the MPCs for 25 *A*. *baumannii* (62.5%) and 25 *K*. *pneumoniae* (75.8%) isolates were 128 mg/L. The high MPC values in this study suggest the possibility of enriching colistin-resistant mutant subpopulations during treatment with colistin monotherapy.\(^6\) Thus, our MPC data may explain the emergence of colistin resistance in Gram-negative pathogens. In reality, the emergence of colistin resistance or heteroresistance after colistin treatment has been reported in *A. baumannii*,\(^7\) and colistin-resistant mutants can be easily selected in vitro.\(^8\) The recommended dose regimen of colistin methanesulphonate of approximately 4–6 mg/kg/day lies within the MSW,\(^9\) which may be linked to the generation of colistin resistance. Since the use of high concentrations of colistin would involve a risk of toxicity,

<table>
<thead>
<tr>
<th>Species/isolate</th>
<th>Colistin MIC (mg/L)</th>
<th>Colistin MPC (mg/L)</th>
<th>Amino acid alterations</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>A. baumannii</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C072</td>
<td>0.5</td>
<td>(&gt;128)</td>
<td>P233S NA NA NA NA</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>2</td>
<td>64</td>
<td>N24S Q232E G361R</td>
</tr>
<tr>
<td>P10</td>
<td>2</td>
<td>(&gt;128)</td>
<td></td>
</tr>
<tr>
<td>P29</td>
<td>1</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>P70</td>
<td>2</td>
<td>(&gt;128)</td>
<td>V281I K123E</td>
</tr>
<tr>
<td>P83</td>
<td>1</td>
<td>(&gt;128)</td>
<td>N188H L181, S24N G361R</td>
</tr>
<tr>
<td>P88</td>
<td>2</td>
<td>64</td>
<td>Syn</td>
</tr>
<tr>
<td>P112</td>
<td>2</td>
<td>64</td>
<td>Syn</td>
</tr>
<tr>
<td>P147</td>
<td>2</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>P155</td>
<td>1</td>
<td>(&gt;128)</td>
<td>R214H</td>
</tr>
<tr>
<td>P179</td>
<td>2</td>
<td>128</td>
<td>V184G</td>
</tr>
<tr>
<td>P185</td>
<td>2</td>
<td>128</td>
<td>V281I Q133E</td>
</tr>
<tr>
<td>P199</td>
<td>2</td>
<td>128</td>
<td>A207R</td>
</tr>
<tr>
<td>P206</td>
<td>2</td>
<td>128</td>
<td>Syn</td>
</tr>
<tr>
<td>P213</td>
<td>2</td>
<td>128</td>
<td>N104I</td>
</tr>
<tr>
<td><em>K. pneumoniae</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>513 BTB</td>
<td>0.5</td>
<td>(&gt;128)</td>
<td>(\Delta) nt position 14</td>
</tr>
<tr>
<td>507 BTB</td>
<td>0.5</td>
<td>(&gt;128)</td>
<td>T157P NA NA</td>
</tr>
<tr>
<td>08-u-899</td>
<td>&gt;128</td>
<td>S208N, (\Delta) nt position 209</td>
<td></td>
</tr>
<tr>
<td>K08-Bact-08-039</td>
<td>4</td>
<td>(&gt;128)</td>
<td>S174N NA NA</td>
</tr>
<tr>
<td>YDJ</td>
<td>0.5</td>
<td>(&gt;128)</td>
<td>T157P NA NA</td>
</tr>
</tbody>
</table>

NA, not applicable; Syn, synonymous mutation; \(\Delta\) nt, three nucleotide deletion.
combination therapy would be recommended to prevent the emergence of colistin resistance by mutant selection.

The emergence of resistance after exposure to antimicrobial agents may be due to the selection of antimicrobial-resistant subpopulations or the occurrence of new mutants through antibiotic stress. Mutations in two-component systems and LpxACD cause colistin resistance due to the modification of lipopolysaccharides in Gram-negative bacteria.

Among 40 *A. baumannii* isolates, an amino acid alteration was identified only in a single-step mutant of one isolate, which showed a P233S substitution in PmrB in CO72 (Table 1), as has been reported in a previous study. No LpxACD mutations were found in this study. In *P. aeruginosa*, amino acid alterations of PmrAB, PhoPQ and ParRS were observed in 12 single-step mutants (Table 1). Double amino acid substitutions were observed in the single-step mutants of four *P. aeruginosa* isolates (P70, P83, P88 and P185). V281I in PmrB and G361R in ParS were each present in two mutants. In *K. pneumoniae*, three kinds of amino acid substitution were observed: S174N in PhoQ and T157P and S208N in PmrB. A T157P substitution was identified in the single-step mutants of two *K. pneumoniae* isolates, 507 BTB and YDJ. Unlike *A. baumannii* and *P. aeruginosa*, amino acid deletions were identified in *pmrB* of two single-step mutants of *K. pneumoniae*. In the single-step mutant of 08-u-899, amino acid substitution and deletion were both identified.

Our results indicate that amino acid alterations of PmrAB, PhoPQ and ParRS occurred in vitro within the period of selection of single-step mutants. This suggests that colistin treatment can provoke genetic mutations related to resistance as a mutagen within a short period in addition to the selection of resistant subpopulations. In short, colistin resistance may occur very easily during drug use.

In summary, we identified high MPCs of colistin for imipenem-susceptible and imipenem-resistant *A. baumannii*, *P. aeruginosa* and *K. pneumoniae* clinical isolates. In single-step mutants, several amino acid substitutions of two-component regulatory systems, PmrAB, PhoPQ or ParRS, were also identified. These findings suggest the possibility of the rapid emergence and spread of colistin resistance by a single mutation. Thus, combination therapy for colistin treatment of non-fermenter and Enterobacteriaceae infections would be necessary to prevent or slow the emergence of colistin resistance.

Acknowledgements

Some *A. baumannii*, *P. aeruginosa* and *K. pneumoniae* isolates used in this study were obtained from the Asian Bacterial Bank (ABB) of the Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Korea.

Funding

This research was supported by the Basic Science Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-00004848).

Transparency declarations

None to declare.

References


Quality control ranges for tylosin 30 µg and 15 µg discs applicable to Staphylococcus aureus ATCC® 25923

Monika Buß1,2, Andrea T. Feßler1,†, John Turnidge3, Thomas Peters2 and Stefan Schwarz1*

1 Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut (FLI), Neustadt-Mariensee, Germany; 2Milchtierherden- Betreuungs- und Forschungsgesellschaft mbH (MBFG), Wunstorf, Germany; 3University of Adelaide and SA Pathology at Women’s and Children’s Hospital, Adelaide, South Australia, Australia

*Corresponding author. Tel: +49-5034-871-241; Fax: +49-5034-871-143; E-mail: stefan.schwarz@ffi.bund.de
†These authors contributed equally to this study.

Keywords: macrolides, disc diffusion, susceptibility testing

J Antimicrob Chemother 2014
doi:10.1093/jac/dkt309
Advance Access publication 8 August 2013

Quality control ranges for tylosin 30 µg and 15 µg discs applicable to Staphylococcus aureus ATCC® 25923